Is Semaglutide Safe for Long-Term Use? Here’s What the Research Actually Says

When Novo Nordisk’s semaglutide trials began publishing results showing 15% or more average body weight reduction, the medical community took notice in a way it rarely does for a pharmaceutical intervention. But as prescriptions have skyrocketed — and as men are now using this drug for years, not just months — a legitimate and pressing question has moved to the forefront: what does long-term use actually look like, and is it safe?

The short answer, based on current evidence, is cautiously optimistic. But the full picture is more nuanced than either the enthusiasts or the skeptics are letting on. And if you’re a man who’s either using semaglutide, considering it, or simply trying to understand where it fits in the broader landscape of metabolic health, the details matter enormously.

What the Clinical Evidence Actually Shows

The foundational clinical case for semaglutide’s long-term safety comes from large-scale trials and guideline bodies that have reviewed the cumulative evidence. The American Gastroenterological Association, in its 2022 Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity, concluded that long-term pharmacological therapy — including semaglutide — is not only recommended for patients with inadequate response to lifestyle intervention alone, but that the drug has demonstrated both efficacy and a manageable safety profile. This wasn’t a fringe opinion. It was the conclusion of a multidisciplinary panel using the rigorous GRADE framework to evaluate the full body of evidence.

On the efficacy side, a 2025 scoping review published in Health Technology Assessment analyzed 22 network meta-analyses of GLP-1 receptor agonists for weight loss. Among its key findings: subcutaneous semaglutide 2.4 mg was associated with 11.5 to 12.5 kg of weight loss compared to placebo — making it one of the two most effective pharmacological options currently available, alongside tirzepatide. That’s meaningful, clinically significant weight loss that translates into real metabolic improvements. But the same review was candid about limitations: there’s a genuine lack of long-term safety data beyond 72 weeks, and head-to-head comparisons with tirzepatide over extended durations simply don’t exist yet. That gap in the evidence is important context for any man making a decision about prolonged use.

The side effect profile that has emerged across trials is fairly consistent. Gastrointestinal effects — nausea, vomiting, constipation, diarrhea — are the most common complaints, particularly during dose escalation. These tend to diminish over time for most users, though a meaningful percentage of patients discontinue treatment due to GI intolerance. More serious adverse events, including pancreatitis and gallbladder disease, have been flagged in the data, though absolute risk remains low. The scoping review noted that tirzepatide and semaglutide 2.4 mg, as the most effective weight loss drugs, were generally associated with a higher risk of safety issues compared to placebo — an honest and important acknowledgment that more powerful interventions come with more significant pharmacological footprints.

The Muscle Mass Question Every Man Needs to Understand

Here’s where the long-term safety conversation gets considerably more complex — and where men, in particular, need to pay close attention. Semaglutide doesn’t just cause you to lose fat. It causes you to lose weight, and a substantial portion of that weight is lean mass. A 2025 review in Reviews in Endocrine and Metabolic Disorders reported that approximately 45% of weight lost with semaglutide comes from lean mass — compared to roughly 25% with tirzepatide. That’s not a minor footnote. For a man losing 20 pounds on semaglutide, that’s potentially 9 pounds of muscle walking out the door with it.

For younger men with plenty of muscle reserve, this is a manageable concern if it’s actively addressed through resistance training and adequate protein intake. But the picture shifts significantly for older men. A 2025 narrative review in the International Journal of Obesity specifically examining obesity pharmacotherapy in adults over 60 highlights this tension: while AOMs including semaglutide can enhance weight loss and reduce cardiometabolic events, the accelerated loss of muscle and bone that accompanies aging past 60 makes lean mass preservation a critical consideration. The authors emphasize that lifestyle interventions — particularly resistance training — remain the cornerstone of obesity management in older adults, with pharmacotherapy serving as an adjunct rather than a replacement.

This isn’t an argument against long-term semaglutide use. It’s an argument for using it intelligently. The men getting the best outcomes on these medications are the ones who treat the drug as a metabolic tool — not a passive solution. They’re lifting weights three to four days per week, prioritizing protein at 0.7 to 1 gram per pound of bodyweight, and tracking body composition rather than just the number on the scale. Without that foundation, semaglutide’s long-term use risks leaving you lighter but metabolically weaker — less muscle, potentially diminished bone density, and a physique that doesn’t match the health improvements happening internally.

Research into mitigating this lean mass loss is active and genuinely promising. The 2025 Ryan et al. review notes that combining GLP-1 receptor agonists with agents targeting the glucagon or amylin pathways may reduce lean mass loss going forward. Myostatin-activin pathway inhibitors, including bimagrumab, are also under investigation and showing early positive signals. But these are future solutions. Right now, the best intervention available to any man on semaglutide is a structured resistance training program and a high-protein dietary strategy — full stop.

What This Means For You

The evidence doesn’t support either extreme in the public debate around semaglutide’s long-term safety. It isn’t a risk-free miracle, and it isn’t the dangerous shortcut that some critics frame it as. What the research supports is a more measured conclusion: semaglutide is a clinically validated, guideline-endorsed intervention with a meaningful and manageable safety profile — but one that demands active participation from the person using it.

If you’re using semaglutide long-term, your non-negotiables are resistance training and sufficient protein. These aren’t optional add-ons — they’re the difference between coming out of treatment leaner and stronger versus lighter but depleted. Get regular monitoring from your physician, including metabolic panels and, if you’re over 50, bone density assessments. Be honest about GI side effects that don’t resolve after the dose escalation phase — persistent severe symptoms warrant a conversation with your doctor about dosing adjustments or alternatives.

If you’re not on semaglutide but evaluating it, understand that the longer-term safety data beyond 18 months remains limited, and researchers are still working to characterize the full picture. That’s not a reason to avoid it if it’s clinically indicated — the AGA guideline makes clear that the risk-benefit profile favors use in appropriate candidates. But it is a reason to stay engaged with the evolving literature and maintain regular clinical follow-up rather than treating this as a set-and-forget prescription.

The men who will look back on their time using semaglutide as a genuine turning point are the ones who used the appetite suppression and weight loss as a runway to build better habits — not as a substitute for them. The drug can open a door. What you walk through it with is still up to you.